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Abstract
The growth of solid tumors depends on neovascularization. Several therapies targeting tumor angiogenesis have
been developed. However, poor response in some tumors and emerging resistance necessitate further investigations
of new drug targets. Notch signal pathway plays a pivotal role in vascular development and tumor angiogenesis. Either
blockade or forced activation of this pathway can inhibit angiogenesis. As blocking Notch pathway results in the
formation of vascular neoplasm, activation of Notch pathway to prevent tumor angiogenesis might be an alternative
choice. However, an in vivo deliverable reagent with highly efficient Notch-activating capacity has not been developed.
Here, we generated a polypeptide, hD1R, which consists of the Delta–Serrate–Lag-2 fragment of the human Notch
ligand Delta-like 1 and an arginine-glycine-aspartate (RGD) motif targeting endothelial cells (ECs). We showed that
hD1R could bind to ECs specifically through its RGD motif and effectively triggered Notch signaling in ECs. We
demonstrated both in vitro and in vivo that hD1R inhibited angiogenic sprouting and EC proliferation. In tumor-bearing
mice, the injection of hD1R effectively repressed tumor growth, most likely through increasing tumor hypoxia and
tissue necrosis. The amount andwidth of vessels reduced remarkably in tumors ofmice treatedwith hD1R.Moreover,
vessels in tumors of mice treated with hD1R recruited more NG2+ perivascular cells and were better perfused.
Combined application of hD1R and chemotherapy with cisplatin and teniposide revealed that these two treatments
had additive antitumor effects. Our study provided a new strategy for antiangiogenic tumor therapy.
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Introduction
It has been recognized for decades that solid tumors require neo-
vascularization essentially through angiogenesis [1,2]. Tumor cells
and other microenvironmental cells secrete angiogenic factors such as
vascular endothelial growth factor (VEGF) and platelet-derived growth
factor, which cooperate with other molecules to fulfill angiogenesis
in tumors. Therapies targeting tumor angiogenic factors have been
developed [3–7], but poor responses in some tumors and emerging
resistance have prompted further investigations of new drug targets
and strategies [8–10].
The Notch signal pathway plays a pivotal role in physiological vas-
cular development [11–16] and tumor angiogenesis [15,17–22]. In
mammals, the canonical Notch pathway is composed of five Notch
ligands [Delta-like (Dll) 1, 3, 4, Jagged 1, 2], four Notch receptors
(Notch1–4), the transcription factor RBP-J, and the downstream
Abbreviations: Dll1, Delta-like 1; ECs, endothelial cells; HUVECs, human umbilical
vein endothelial cells; RGD, arginine-glycine-aspartate; NICD, intracellular domain of
Notch receptors
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effectors such as the Hes family molecules [11]. The Notch ligand–
receptor interaction mediated by the Delta–Serrate–Lag-2 (DSL) do-
mains of the ligands triggers serial proteolytic cleavages of receptors,
which release the intracellular domain of Notch receptors (NICD).
NICD further associates with RBP-J and transactivates downstream
genes involved in multiple steps of angiogenesis including sprouting,
extension, and maturation of neovasculature [11,12,17].
Blocking Notch signal inhibits tumor growth through nonproduc-
tive angiogenesis [20–24], but this treatment results in the formation of
vascular neoplasms [25]. Activating Notch pathway may be an alter-
native way to modulate angiogenesis because forced activation of endo-
thelial Notch signaling also inhibits angiogenesis [19,26–29]. However,
although a soluble DSL domain of Dll1 is sufficient for triggering
Notch signal in vitro, it might be inefficient or even inhibitory to Notch
signal activation in vivo, because of their incompetence in inducing
endocytosis of Notch ligands on the signal-sending cells, a necessary
step for Notch activation [30,31]. To produce a soluble Notch ligand
with a better capability to induce endocytosis in vivo, we designed
a fusion protein, hD1R, which is composed of the DSL domain of
the human (h)Dll1 (amino acids 127–225) and an arginine-glycine-
aspartate (RGD)–containing nonapeptide (CRGDCGVRY). RGD tar-
gets the integrin αvβ3 expressed on endothelial cells (ECs) in response
to angiogenic growth factors and tumors [32–34] and it has been
shown that the binding of RGD-containing molecular ligands with cell
surface integrins triggers endocytosis [35]. In this study, we demon-
strated that hD1R can effectively trigger Notch signaling in ECs and
inhibit angiogenesis and tumor growth, thus providing a novel strategy
for antiangiogenic tumor therapy.
Materials and Methods
Expression of Recombinant Proteins in Escherichia coli
The cDNA fragment encoding the DSL domain of hDll1
(NM_005618) was amplified by using polymerase chain reaction
(PCR) from a human cDNA library. The product was fused with an
RGD motif (hD1R) or a DGR motif (hD1D) by PCR. The PCR
primers are listed in Table W1. The resultant gene fragments were
cloned into pET32a(+) between the NcoI and XhoI sites to construct
pET32a-hD1S (stop), pET32a-hD1R (RGD fusion), and pET32a-
hD1D (DGR fusion), respectively (Figure 1A). For the production
of the recombinant proteins, E. coli BL21 was transformed with the
plasmids. Positive clones were expanded in Luria-Bertani medium,
and cells at the exponential stage were induced with 0.5 mM isopropyl
β-D-thiogalactoside. The Trx-hD1S, Trx-hD1R, and Trx-hD1D pro-
teins were purified by using Ni2+-NTA columns (Invitrogen, Carlsbad,
CA) according to the manufacturer’s manuals. To obtain the S-tagged
hD1S, hD1R, and hD1D proteins, Trx-hD1S, Trx-hD1R, and
Trx-hD1D were cleaved by using thrombin (Novagen, Darmstadt,
Germany) and further purified by using Ni2+-NTA columns following
the supplier’s instructions. For Western blot, proteins were separated
by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-
PAGE) and electroblotted onto polyvinylidene difluoride (PVDF)
membrane. Membranes were probed by using anti-His (Sigma,
St Louis, MO) or anti–S-Tag antibody (Novagen) at appropriate dilu-
tions, followed by incubation with an HRP-conjugated secondary
anti-mouse IgG antibody (Millipore, Billerica, MA). Blots were devel-
oped by using the enhanced chemiluminescence system (Clinx Science
Instruments, Shanghai, China).
Cell Culture
The tumor cell lines U87, LLC, andMCF-7 (ATCC,Manassas, VA)
were maintained in RPMI 1640medium (Invitrogen) supplemented with
10% FBS, 2 mM L-glutamine, 100 IU/ml penicillin, and 100 μg/ml
streptomycin sulfate. Human umbilical vein ECs (HUVECs) were cul-
tured in the endothelial cells media (ECM; ScienCell, San Diego, CA)
supplemented with 10% FBS, 100 IU/ml penicillin, 100 μg/ml strepto-
mycin, and endothelial cell growth supplement (ECGS; ScienCell). The
recombinant hD1S, hD1D, or hD1R was added at the concentration
of 1 μg/ml. γ-Secretase inhibitor (GSI; DAPT; Alexis Biochemicals,
San Diego, CA) and Dynasore (Sigma) were used at the concentration
of 75 and 40 μM, respectively. For the cell adhesion assay, wells of
96-well dishes were coated with 100 μl of different recombinant proteins
(50 μg/ml) overnight, and then 1 × 105 HUVECs were seeded in each
well. In some cases, an RGD peptide (CRGDCGVRY) or a DGR pep-
tide (CDGRCGVRY; CL Bio-Scientific, Xi’an, China) was included at
the concentration of 1 μg/ml. Cells were cultured for 1.5 hours, and non-
adhesive cells were discarded by rinsing with phosphate-buffered saline
(PBS). Adherent cells were stained with crystal violet, photographed,
and quantified by light absorbance at A620 using a spectrometer.
Flow Cytometry
For flow cytometry, single-cell suspensions were prepared from cul-
tured cells or mouse lymphoid tissues and stained with appropriate
antibodies. Then, cells were analyzed by using a FACSCalibur flow
cytometer (BD Immunocytometry Systems, San Jose, CA) and the
CellQuest software. Dead cells were excluded using propidium iodide
staining. S-Tag was stained with a rabbit anti–S-Tag antibody followed
by fluorescein isothiocyanate–conjugated goat anti-rabbit IgG (Santa
Cruz Biotechnology, Inc, Santa Cruz, CA). Other antibodies used
for staining were given as follows: anti-CD19 (1D3; BD Pharmingen,
San Jose, CA), anti-CD21 (7G6; Biolegend, SanDiego, CA), anti-CD23
(B3B4; Biolegend), anti-CD3 (145-2C11; Biolegend), anti-CD4
(RM4-5; BD Pharmingen), and anti-CD8 (53-6.7; BD Pharmingen).
Quantitative Reverse Transcription–PCR
Total RNA was extracted by using the TRIzol reagent (Invitrogen)
according to the manufacturer’s instructions. cDNA was prepared by
using a reverse transcription (RT) system (Takara Dalian, Dalian, China).
Quantitative real-time PCR was performed in triplicates by using a kit
(SYBR Premix EX Taq; Takara) and the ABI PRISM 7500 Real-Time
PCR System, with β-actin as an internal control. The PCR primers are
listed in Table W1.
Fibrin Bead Assay
HUVECs were tested for angiogenic sprouting with the fibrin bead
assay using a kit (Amersham Pharmacia Biotech, Piscataway, NJ)
according the supplier’s instructions [36]. Briefly, HUVECs were
cultured in EGM-2 medium (Clonetics, Walkersville, MD) the day
before beading. Cytodex 3 microcarrier beads (Amersham) were pre-
pared according to the supplier’s instructions, and the beads were
incubated with HUVECs (400 cells per bead) at 37°C for 4 hours.
The coated beads were transferred to a tissue culture flask (T25; Falcon,
Bedford, MA) and left overnight in 5 ml of EGM-2 at 37°C and 5%
CO2. The beads were washed three times and were suspended at a
density of 500 beads/ml in the fibrinogen solution with 0.625 U/ml
thrombin, and the fibrinogen/bead suspension (0.5 ml) was distributed
in each well of a 24-well plate. After clotting at room temperature for
5 minutes and then at 37°C and 5% CO2/95% air for 15 minutes,
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EGM-2 (1 ml) was added to each well slowly and lung fibroblasts were
seeded on top of the clot at a concentration of 20,000 cells/well. PBS,
hD1R, DMSO, or GSI was included depending on the experiments.
Images of the beads were captured by using an inverted microscope
(CKX41; Olympus, Tokyo, Japan) with a charge-coupled device
(CCD) camera (DP70; Olympus), and the number and length of the
sprouts were measured.
Endothelial Network Formation Assay
Matrigel Basement Membrane Matrix (BD Biosciences) was
thawed overnight at 4°C and diluted with medium to coat wells of
48-well dishes at 37°C for 30 minutes. HUVECs (1 × 105) were
seeded on the gel in 400 μl of medium and incubated at 37°C
and 5% CO2 for 3 hours. hD1S or hD1R was added simultaneously
when the cells were seeded at the concentration of 1 μg/ml. Images
were captured by using a converted microscope with a CCD camera.
The network formation was quantified by counting branches and the
length of the enclosed lumens.
Tumor-bearing Mouse Models. Tumor cells (5 × 106) were in-
jected subcutaneously (s.c.) into nude mice brought about under
specific pathogen–free conditions. PBS or hD1R (80 μg/injection)
was injected intraperitoneally (i.p.) twice per week from the 7th day
of the tumor inoculation. In some cases, cisplatin or teniposide were
administrated i.p. at the concentration of 5 mg/kg once a week. Tumor
growth was monitored by measuring the tumor length (L) and short
(S) with a sliding caliper from the 7th day of tumor inoculation (tumor
size = L × S2 × 0.51). On the ending day of the experiment, the body
weights of the mice were recorded before being sacrificed. Tumors
were removed, weighed, and used for further histologic examinations.
Tumor weight index was calculated as the ratio of tumor weight versus
body weight. All animal experiments were approved by the Animal
Experiment Administration Committee of the university.
Histology
Tissues were fixed by immersing in 4% paraformaldehyde for
2 hours at 4°C, followed by immersing in 25% sucrose in PBS overnight.
The samples were embedded in optimal cutting temperature (OCT)
Figure 1. EC-targeted hDll1 efficiently activated Notch signaling. (A) Schematic representatives of recombinant proteins. Trx, His, S,
DSL, RGD, and DGR indicate thioredoxin, His tag, S tag, DSL domain of hDll1, RGD peptide, and DGR peptide, respectively. The site
of thrombin cleavage is indicated with an arrow. (B) HUVECs were incubated with PBS, hD1S, hD1R, or hD1D and examined by FACS
after secondary staining with anti–S-Tag. (C) hD1R activates Notch signaling in RGD- and GSI-dependent ways. HUVECs were incubated
with PBS, hD1S, hD1R, or hD1D for 24 hours. GSI was included in some of the cultures as indicated. Cells were stained by immuno-
fluorescence using anti-NICD. The intensity of fluorescent signals per cell was quantified and shown in the inset. (D) HUVECs were
treated as in C. Cells were harvested and the expressions of Hes1 and Hey1 were detected by quantitative RT-PCR. (E) Activation of
Notch signaling by hD1R required endocytosis. HUVECs were incubated with PBS or hD1R for 24 hours. DMSO or Dynasore was in-
cluded in the medium as indicated. The expression of Hes1 and Hey1 was detected by using quantitative RT-PCR. (F) Activation of
endothelial Notch signaling by hD1R in vivo. P3 pups were injected daily s.c. with PBS, hD1S, or hD1R. On P7, the retinas of the pups
were collected and used for real-time RT-PCR for the expression of Hes1, VEGFR1, and VEGFR2, with CD31 as a reference control. Bars,
means ± SD. *P < .05, **P < .01, n = 5.
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compound (Sakura Finetek, Inc,Torrance,CA), sectioned at 10-μmthick-
ness, and then dried at room temperature for 2 hours. Hematoxylin and
eosin (H&E) staining was performed according to routine protocols.
For immunofluorescence staining, cryosections were blocked with
1% BSA in PBS and then incubated with rat anti-CD31 (Biolegend),
rabbit anti–S-Tag (Abcam, Cambridge, MA), rabbit anti-NG2
(Millipore), or rabbit anti-Ki67 (Thermo Scientific, Fremont, CA) as
the primary antibodies. After washing, sections were incubated with
secondary antibodies including biotinylated goat anti-rat secondary
antibody (Vector Laboratories, Burlingame, CA), Cy3-conjugated goat
anti-rabbit IgG (Sigma), or fluorescein isothiocyanate–conjugated goat
anti-mouse IgG (Sigma). In some cases, Cy3-conjugated streptavidin
(Sigma) or DyLight 488 streptavidin (Vector Laboratories) was ap-
plied. Images were acquired under a fluorescence microscope (BX51;
Olympus) or a confocal microscope (FV1000; Olympus). Cultured
cells were stained in a similar way by using rabbit anti–S-Tag or rabbit
anti-NICD (Abcam), followed by Cy3-conjugated goat anti-rabbit
IgG (Sigma), and observed under a microscope.
For whole-mount staining of retinal vasculature, postnatal day 3 (P3)
pups were injected s.c. with PBS, GSI, or hD1R (25 μg) once a day.
Retinas were collected on P7, flat-mounted, and fixed in 4% para-
formaldehyde for 2 hours. The samples were permeabilized with
0.2% Triton X-100 for 2 hours and then stained with fluorescein-
labeledGriffonia simplicifolia Lectin I (Vector Laboratories) for 24 hours
at 4°C. After washing, images were taken under a fluorescence micro-
scope or a confocal microscope.
To visualize hypoxic regions in tumors, pimonidazole HCl (60 mg/
kg; Hypoxyprobe Inc, Burlington, MA) was injected i.p. into mice
1 hour before sacrifice. Anesthetized mice were then perfused with
4% paraformaldehyde solution in 0.1 M phosphate buffer (pH 7.2).
Tumors were sectioned and stained by using rabbit anti-Hypoxyprobe
(PIMO) antibody (Hypoxyprobe Inc) and Cy3-conjugated goat anti-
rabbit (Sigma). To detect perfused blood vessels, a biotinylated lectin
(Lycopersicon esculentum, 100 μg; Vector Laboratories) was injected
intravenously through the tail veins, and the mice were sacrificed
30 minutes later. Tumors were subsequently fixed by perfusion with
paraformaldehyde solution as above.
Sample preparation and observation with scanning electron micro-
scope (SEM) were as described [37].
Statistics
Pixels for each color were calculated by using Image Pro Plus 6.0
software to quantitatively represent the intensity of positive cells.
Statistical analysis was performed with the SPSS 12.0 program. Com-
parisons between groups were undertaken using unpaired Student’s
t test. Results were expressed as means ± SD. P < .05 was considered
statistically significant.
Results
hD1R Efficiently Bound to ECs
Recombinant Trx-hD1R was manufactured in E. coli and puri-
fied by using Ni2+-NTA columns. The product was cleaved with
thrombin followed by affinity chromatography to obtain hD1R with
an S-Tag at the N terminus (Figures 1A and W1). hD1S (the DSL
domain of hDll1 with a stop codon at the C terminus) and hD1D (the
DSL domain of hDll1 fused with a DGR-containing nonapeptide,
CDGRCGVRY) were produced as well and employed as controls.
To evaluate the binding activity of hD1Rwith ECs, HUVECs were
incubated with PBS, hD1S, hD1D, or hD1R and then subjected to
indirect immunofluorescent staining with an anti–S-Tag antibody, fol-
lowed by fluorescence-activated cell sorting (FACS) analysis. The result
showed that hD1R but not hD1S or hD1D could bind to HUVECs
(Figure 1B). This was confirmed by the observation that displayed
significant staining of HUVECs incubated with hD1R but not hD1S
or hD1D under a fluorescence microscope (FigureW2). Moreover, in a
cell adhesion assay, we found that more HUVECs adhered to culture
dishes precoated with hD1R than to dishes precoated with hD1S or
hD1D. The adherence of HUVECs to hD1R-coated dishes could be
blocked by a synthetic RGD nonapeptide but not by a DGR non-
apeptide (Figure W3). These results demonstrated that hD1R could
efficiently bind to HUVECs, most likely through the RGD motif. In
addition, co-immunoprecipitation assay also showed that hD1R could
interact with the extracellular domain of Notch1 (Figure W4).
Activation of Endothelial Notch Signaling by hD1R
In HUVECs incubated with hD1R, immunofluorescence staining
and Western blot analysis showed an increase in the level of NICD,
which was abrogated by GSI (Figures 1C andW5). In contrast, neither
hD1S nor hD1D enhanced NICD level in HUVECs. Consistently,
the mRNA level of Hes1 and Hey1, two major Notch downstream
targets in ECs, increased remarkably in a γ-secretase–dependent way
in hD1R-treated, but not hD1S- or hD1D-treated, HUVECs (Fig-
ure 1D). Interestingly, the hD1R-inducedNotch activation in HUVECs
was blocked by the dynamin inhibitor Dynasore (Figure 1E), consistent
with the assumption that the RGD motif of hD1R most likely medi-
ated the endocytosis of hD1R, which is essential for efficient Notch
Figure 2. hD1R repressed angiogenesis both in vitro and in vivo. (A, B) HUVECsweremixed with Cytodex 3 microbeads (400 cells per bead)
and cultured for 24 hours for angiogenic sprouting in the presence of PBS, hD1R, hD1S, DMSO, or GSI. Each sprout was labeled with a
red dot (A) and the numbers of sprouts and the sprout length per bead were counted and compared (B). (C, D) HUVECs were cultured in
48-well dishes coated with Matrigel Basement Membrane Matrix in the presence of PBS, hD1S, or hD1R. Cells were cultured under the
indicated conditions for 3 hours and photographed under a microscope (C). The formation of endothelial networks was quantified by count-
ing branch points and length of cells along the lumens (D) and compared. (E, F) P3 pups were injected daily s.c. with PBS or hD1R. On P7,
the retinas of the pups were collected, flat-mounted, and stained with fluorescein-labeled Griffonia simplicifolia Lectin I. The structures
of the whole retinal vasculature were shown (E). The numbers of enclosed capillary loops and vessel branch points were compared (F).
(G, H) P3 pups were injected daily s.c. with PBS, GSI, or hD1R. On P7, the retinas of the pups were collected, flat-mounted, and stained
with fluorescein-labeled Griffonia simplicifolia Lectin I. Tip cells at the angiogenic fronts were counted (G) and compared (H). (I, J) P3 pups
were injected daily s.c. with PBS or hD1R. On P7, the retinas of the pups were collected and sectioned. The samples were co-stained
with anti-Ki67 (red) and lectin (green) and were counterstained with Hoechst (I). The Ki67+ signals were compared (J). Bars, means ± SD.
*P < .05, **P < .01, ***P < .001, n = 5.
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activation [30,31]. To evaluate the ability of hD1R to activate Notch
signaling in vivo, purified hD1R was injected s.c. into P3 pups. The
developing retinal vasculature was isolated on P7, and the expressions
of Hes1, VEGF receptor 1 (VEGFR1), and VEGFR2 were assessed
with quantitative RT-PCR. The results showed that the treatment with
hD1R significantly elevated the expression of Hes1 and VEGFR1 while
reduced the expression of VEGFR2, in line with Notch activation in
ECs (Figure 1F). These results suggested that hD1R could efficiently
activate Notch signaling in ECs.
hD1R Repressed Angiogenesis In Vitro and In Vivo
We then employed in vitro assays to examine the effects of hD1R on
angiogenic sprouting and lumen formation by ECs. A fibrin gel bead
assay was established with HUVECs in the presence of PBS, hD1R,
hD1S, DMSO, or GSI, and the numbers of sprouts on each bead
were counted. The result showed that hD1R significantly reduced
the number and the length of the sprouts under the sprouting con-
dition (Figure 2, A and B). Moreover, HUVECs were cultured in a
Matrigel Basement Membrane Matrix in the presence of PBS, hD1S,
or hD1R, and the formation of endothelial networks was compared
by counting network branches and lengths. The result showed that
hD1R dramatically inhibited network formation by HUVECs (Fig-
ure 2,C andD). Collectively, these data suggested that hD1R repressed
angiogenesis in vitro.
We next examined the effects of hD1R on retinal angiogenesis. Pups
were injected daily s.c. with PBS or hD1R from P3, and the angiogenic
sprouting of retinal vasculature was examined on P7 by whole-mount
retinal staining with lectin. The comparison of the number of capillary-
enclosed loops and the number of vessel branch points indicated that
the administration of hD1R significantly reduced the density of retinal
vasculature in the distal and middle areas compared with the control.
The vessel density in the proximal areas of retinal vasculature appeared
not to be affected by hD1R administration, in line with the fact that
angiogenesis had been completed in these areas (Figures 2, E and F ,
and W6). In addition, as shown in Figure 2, G andH , consistent with
the in vitro observations, hD1R reduced while GSI increased the num-
ber of tip cells at the angiogenic fronts. Furthermore, to inspect the
effects of hD1R on endothelial proliferation, we injected P3 pups s.c.
Figure 3. hD1R inhibited tumor growth. (A) U87, LLC, and MCF-7 cells were inoculated s.c. in nude mice. The mice were injected i.p. with
PBS or hD1R twice a week from the 7th day of the tumor inoculation. The growth of tumors was monitored by measuring tumor size twice
a week from the 7th day after tumor cell inoculation. (B) Tumors were dissected on the last day of the experiments, and tumor weight
indexes were calculated and compared. (C) MCF-7 cells were inoculated s.c. in nude mice. The mice were injected i.p. with PBS, ChT,
hD1R, or hD1R plus ChT from the 7th day of the tumor inoculation. The growth of tumors was monitored by measuring tumor size twice
a week from the 7th day after tumor cell inoculation. (D) Tumors were dissected on the last day of the experiments, and tumor weight
indexes were calculated and compared. Bars, means ± SD. *, #P < .05, **, ##P < .01, ***P < .001, n = 8.
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with PBS or hD1R and observed the proliferation of retinal ECs on
P7 by immunofluorescent staining of the Ki67 antigen on lectin-
marked ECs in retinal sections. The result showed that the numbers
of Ki67+ ECs decreased remarkably in retinas of pups injected with
hD1R (Figure 2, I and J ). These in vivo data demonstrated that
hD1R inhibited angiogenesis, most likely by suppressing the formation
of tip cells and EC proliferation.
hD1R Repressed Tumor Growth
We investigated the effects of hD1R on tumor growth. In a pre-
liminary experiment, U87 human glioma cells were inoculated s.c. in
nude mice. PBS or different dosage (20, 40, 60, and 80 μg/injection)
of hD1R was injected i.p. every 2 days from the 7th day of tumor
inoculation up to the 16th day. Observation of tumor growth
showed that injection of hD1R dose-dependently repressed tumor
growth (data not shown). We then examined the effect of hD1R
on the growth of the U87 and LLC mouse lung cancer cells and
the MCF-7 human breast cancer cells. Tumor cells (5 × 106) were
inoculated s.c. in nude mice. Seven days after the initial inoculation,
when tumor sizes were about 0.05 × 103 mm3, PBS or hD1R was
injected i.p. into tumor-bearing nude mice. As shown in Figure 3A,
in all three types of tumors, hD1R significantly repressed tumor
growth compared with the control group. At the end of the experi-
ment when the tumors were collected, measurement of tumor weight
index also indicated that hD1R significantly repressed tumor growth
(Figure 3B).
To further evaluate the therapeutic efficacy of hD1R in combina-
tion with chemotherapy, MCF7 cells were inoculated s.c. in nude
mice, and the mice were treated with PBS, cisplatin and teniposide
(ChT), hD1R, or hD1R plus ChT from the 7th day of tumor inocu-
lation up to 28th day. Tumor growth was monitored twice a week,
and at the end of the experiment, tumors were collected and assessed
for tumor weight index. The result showed that, while hD1R or ChT
treatment could dramatically reduce tumor growth comparably, com-
bined application of hD1R and ChT further decreased tumor size
significantly compared with the monotreatments (Figure 3C ). This
observation was further supported by tumor weight index analysis
(Figure 3D). These results suggested that hD1R could repress tumor
growth, and hD1R and ChT had additive effects in suppressing
tumors when used together.
Application of hD1R Enhanced Tumor Hypoxia
Histologic examination of tumor tissues by H&E staining showed
that the application of hD1R induced more severe necrosis in tumors
(Figure 4, A and B). We also assessed hypoxia in the tumor tissues
by PIMO perfusion followed by anti-PIMO staining, and the result
Figure 4. hD1R enhanced tumor hypoxia. (A, B) Tumors were dissected on the ending day of the experiments and subjected to H&E stain-
ing (A). Necrosis areas were compared (B). Data from U87 inoculated nude mice were shown. The necrotic areas are marked by asterisks.
(C, D) On the last day of the experiments, mice in A were injected i.p. with PIMO and were sacrificed 1 hour later. Tumors of the PBS and
hD1R groups were dissected, sectioned, and stained with anti-PIMO (C). PIMO+ (hypoxic) areas per field were quantified and compared (D).
Bars, means ± SD. *P < .05, **P < .01, n = 8.
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showed that there were increased PIMO staining signals in all three
types of tumors, indicating enhanced tissue hypoxia in the tumors in
mice treated with hD1R (Figure 4, C and D). These data indicated
that hD1R could repress the growth of solid tumors probably
through increasing hypoxia in tumor tissues.
hD1R Inhibited Neovascularization of Solid Tumors
We next assessed tumor neovasculature in the hD1R-treated
tumor-bearing mice. Tumors were collected from the tumor-bearing
mice treated with PBS or hD1R as above. The density of tumor
vasculature was evaluated by immunofluorescent staining with anti-
CD31. The result showed that the treatment with hD1R significantly
reduced vascular density in all three types of tumors (Figure 5, A and
B). The tumor tissues were also co-stained with anti-CD31 and anti–
S-Tag antibodies, and the result showed that some of the S-Tag+
signals overlapped with the CD31+ signal, suggesting that the S-tagged
hD1R could bind to ECs in tumors (Figure W7). Collectively, these
results indicated that hD1R could reduce tumor neovasculature, most
likely through repressing angiogenic sprouting.
We also inspected the structure of tumor vasculature after treat-
ment with hD1R. Under an SEM, the diameter of vessel lumens
of the hD1R-treated tumors was reduced (Figure 5, C and D), pos-
sibly due to reduced EC proliferation. Moreover, there were fibrous
materials (Figure 5C , yellow arrows) and leakage-like materials
(Figure 5C , red arrows) within and out of microvessels in the con-
trol, and these changes were significantly attenuated in the hD1R-
treated group, suggesting that the structure of the hD1R-treated
tumor vessels might be normalized compared with the controls.
hD1R Enhanced Recruitment of NG2+ Perivascular Cells
Notch signaling could regulate vessel maturation by recruiting peri-
vascular cells including smooth muscle cells (SMCs) and pericytes
[38–42]; therefore, we co-stained the tumor sections with anti-NG2
and anti-CD31. The results showed that the hD1R treatment
increased NG2+ signals in both LLC and U87 tumors (Figures 6,
A–C , and W8, A–C ), suggesting that hD1R treatment promoted
the maturation of tumor neovasculatures while reducing the amount
of tumor vessels. We then examined the function of tumor vasculature
after treatment with hD1R. The tumor-bearing mice treated with PBS
or hD1R were injected intravenously with biotinylated lectin before
being sacrificed, and the tumor sections were co-stained with strepta-
vidin and anti-CD31. The result showed that the vessel density was
reduced, while vessel perfusion was improved in tumors of mice treated
with hD1R (Figures 6, D and E , and W8, D and E ). These results
suggested that hD1R might improve tumor vessel integrity, which
has been shown to be damaged and results in vessel leakage in tumors.
Figure 5. hD1R reduced tumor vasculature. (A, B) U87, LLC, and MCF-7 cells were inoculated s.c. in nude mice. The mice were in-
jected i.p. with PBS or hD1R twice a week from the 7th day of the tumor inoculation. Tumors were dissected on the last day of the
experiments, sectioned, and immunostained with anti-CD31. CD31+ areas per field were quantified and were compared between
groups (B). (C, D) U87 tumors in A were dissected, sectioned, and observed under SEM (original magnification, × 8000). The yellow
arrows and red arrows indicate fibrous materials and leakage-like materials within and outside the microvessels. The shortest inside
diameter of each vessel section (20 vessels for each group) was measured and compared (D). Bars, means ± SD. *P < .05, **P < .01,
***P < .001, n = 8.
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Discussion
Although it has been revealed that both blocking [13–16,20–24] and
activating [19,26–29] Notch signaling result in the disruption of
angiogenesis, therapies targeting Notch pathway remain to be estab-
lished. Because blocking Notch signaling leads to vascular neoplasms
[25], activating Notch signaling might be an alternative choice.
EC-specific, high efficient activation of Notch signaling, however,
is impeded by the facts that Notch ligands are membrane proteins
and the activation of Notch receptors requires ligand-mediated endo-
cytosis [30,31]. In this study, to overcome these obstacles, we tried to
develop a novel soluble Notch ligand, hD1R, in which the receptor-
triggering DSL domain of hDll1 was fused with an EC-targeting
peptide RGD. hD1R did not directly influence tumor cell prolifer-
ation in vitro (data not shown). To interfere with tumor angiogene-
sis, hD1R has the following advantages. First, it is in vivo deliverable
as hD1R can be manufactured in E. coli in a soluble form and can
be administrated by injection. Second, it is EC-targeted because
the RGD motif binds to several types of integrins, some of which
are expressed on ECs in response to angiogenic growth factors and
tumors [32–35]. This may help restrict Notch activation within ECs
and other EC-neighboring cells such as blood cells and some stem
cells. Indeed, by using a mouse counterpart of hD1R, we found that
administration of the recombinant protein in vivo did not affect the
morphology of main organs (data not shown) nor lymphocyte dif-
ferentiation and homeostasis [22,43] (Figure W9). Third, hD1R
exhibits a strong Notch-activating activity given that RGD motif
of hD1R not only provided EC-specific binding capacity but also
triggered endocytosis, a process that is essential to Notch activation
[30,31]. hD1R could therefore be used to activate endothelial Notch
signaling in vivo to inhibit angiogenesis in tumors. Moreover, hD1R
could also be used to repress angiogenesis in other angiogenic diseases
such as age-related macular degeneration [44,45], although an in-
fluence on physiological angiogenesis could not be avoided because
RGD also targets normal vessels.
Administration of hD1R in vivo delays tumor growth and reduces
tumor neovascularization most likely through blocking angiogenic
sprouting. hD1R may also influence other aspects of tumor angio-
genesis including repressing VEGFR2 expression and decreasing
EC proliferation, thus reducing the diameter of vessel lumens. More-
over, the hD1R-treated tumor vessels appeared to be better perfused,
likely due to improved vessel integrity. This could be helpful for
other chemotherapeutics to access tumor cells because a “normalized”
vessel structure might inhibit metastasis [46,47], as reported in the
study of heterozygous deficiency of PHD2 [48]. Indeed, we observed
an additive effect when hD1R was applied together with ChT in
MCF7 xenograft tumor models.
Different Notch ligands show distinct even opposing effects on
angiogenesis [49,50], which is in line with the observed different
roles of hD1R here from reported Dll4 function before. Segarra et al.
reported that Dll4-mediated activation of Notch signaling reduced
tumor vascularity and inhibits tumor growth [26]. However, Li et al.
found that Dll4 reduced the number of tumor blood vessels but im-
proved tumor vascular function [19]. These authors also found that
overexpression of Dll4 on tumor cells promoted tumor growth and
mediated tumor resistance to anti-VEGF therapy [51]. In contrast,
we have shown that the overexpression of Dll1 in tumor cells leads
Figure 6. hD1R enhanced the recruitment of perivascular cells. U87 cells were inoculated s.c. in nude mice, and the mice were treated
with PBS or hD1R. (A–C) Tumors were stained with anti-CD31 (green) and anti-NG2 (red). The NG2+ areas (B) and the ratio of NG2+ areas
versus CD31+ areas (C) were compared. (D, E) On the last day of the experiments, mice were injected with lectin (green) through the tail
vein. Tumors were dissected 30 minutes after the injection and were stained with anti-CD31 (red). The percentage of the perfused vessels
(lectin and CD31 double positive) was counted and compared (E). Bars, means ± SD. *P < .05, **P < .01, ***P < .001, n = 8.
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to reduced tumor growth attributable to attenuated vascularization
[29]. The discrepancy could result from the fact that individual ligands
are expressed in different endothelial territories and interact with dif-
ferent Notch receptors following temporospacial-specific patterns
during angiogenesis [49]. However, hD1R is a diffusable molecule
that may effect on different steps of angiogenesis independent of
temporospacial distribution, resulting in reduced vessel formation
and better perfusion in tumors.
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Table W1. Primers Used in This Study.
Gene Purpose Direction Sequence
Human β-actin RT-PCR Forward 5′-TGGCACCCAGCACAATGAA
Backward 5′-CTAAGTCATAGTCCGCCTAGAAGCA
Human Hes1 RT-PCR Forward 5′-TGGAAATGACAGTGAAGCACCTC
Backward 5′-TCGTTCATGCACTCGCTGAAG
Human Hey1 RT-PCR Forward 5′-CATGAAGAGAGCTCACCCAGA
Backward 5′-CGCCGAACTCAAGTTTCC
Mouse β-actin RT-PCR Forward 5′-CATCCGTAAAGACCTCTATGCCAAC
Backward 5′-ATGGAGCCACCGATCCACA
Mouse Hes1 RT-PCR Forward 5′-AAAGACGGCCTCTGAGCAC
Backward 5′-GGTGCTTCACAGTCATTTCCA
Mouse VEGFR1 RT-PCR Forward 5′-TAATGACGATGGCAACAGGGTAGA
Backward 5′-TGTGCACGACCTAAGCACACAG
Mouse VEGFR2 RT-PCR Forward 5′-GGGATGGTCCTTGCATCAGAA
Backward 5′-ACTGGTAGCCACTGGTCTGGTTG
hD1S Cloning Forward 5′-CGCCATGGTCCACACAGATTCTCCTG
Backward 5′-CGCTCGAGGATCGGCTCTGTGCAGTAG
hD1D Cloning Forward 5′-CGCCATGGTCCACACAGATTCTCCTG
Backward 5′-CGCTCGAGTTAGTATCTAACGCCGCATCTGCCATCGCAGATCGGCTCTGTGCAGTAG
hD1R Cloning Forward 5′-CGCCATGGTCCACACAGATTCTCCTG
Backward 5′-CGCTCGAGTTAGTATCTAACGCCGCAATCGCCTCTGCAGATCGGCTCTGTGCAGTAG
Figure W1. Expression of hD1R, an EC-targeted DSL domain of hDll1. (A) Schematic illustrations of the full-length hDll1, the DSL domain of
hDll1 (hD1S), hDll1 fused with the RGD peptide (hD1R), and hDll1 fused with the DGR peptide (hD1D). (B) E. coli (BL21) was transformed
with pET32(a), pET32a-hD1S, pET32a-hD1D, or pET32a-hD1R. Positive transformants were inducedwith isopropyl β-D-thiogalactoside. Total
cell lysates were analyzed by SDS-PAGE (upper). The gel was blotted onto PVDF membrane and probed with the anti-His antibody (lower).
(C) The recombinant Trx-hD1S, Trx-hD1D, and Trx-hD1R proteins were purified with Ni+-NTA columns and analyzed by using SDS-PAGE.
(D) Trx-hD1R was cleaved with thrombin and purified by using an Ni+-NTA column. The eluent was analyzed by SDS-PAGE (left), followed
by Western blot by using anti–S-Tag.
Figure W2. hD1R could efficiently bind to ECs. HUVECs were in-
cubated with PBS, hD1S, hD1D, or hD1R for 2 hours. Cells were
washed with PBS and fixed with 4% paraformaldehyde. Samples
were then stained with anti–S-Tag plus Cy3-conjugated secondary
antibody and observed under a confocal microscope.
Figure W3. hD1R bound to ECs through the RGD motif. (A) Culture
dishes were coated with PBS, hD1S, hD1D, or hD1R. HUVECs were
distributed into different wells and incubated for 1.5 hours. In some
wells, synthetic DGR or RGD nonapeptide was included. After in-
cubation, wells were washed with medium and nonadherent cells
were discarded. Adherent cells were stained with crystal violet and
photographed. (B) Cells in A were lysed, and A620 in the super-
natants was detected and compared between different groups.
Bars, means ± SD. ***, ###P < .001, n = 4.
Figure W4. hD1S and hD1R could interact with the extracellular
domain of Notch1 receptor. HUVECs were lysed with cell lysis
buffer, and the supernatants were incubated with PBS, hD1S, or
hD1R. Immunoprecipitation was performed with anti–S-Tag, and the
presence of Notch1 extracellular domain was detected by immuno-
blot analysis with anti-Notch1. For methodology, HUVECs were
washed once with ice-cold PBS and lysed in IP buffer (Beyotime,
Haimen, China). Cell lysates were incubated with PBS, S-tagged
hD1S, or S-tagged hD1R for 2 hours at 4°C and then incubated with
protein G-Sepharose beads (Invitrogen) precoated with anti–S-Tag
antibody (1:200; Abcam) overnight. The beads were washed exten-
sively, and co-precipitated proteins were detected by immunoblot
analysis with an anti-Notch1 (Santa Cruz Biotechnology, Inc) as the
primary antibody.
Figure W5. Western blot. (A) HUVECs were incubated with PBS,
hD1S, hD1D, or hD1R for 24 hours. GSI was included in some of
the cultures as indicated. Total cell lysates were prepared and ana-
lyzed by SDS-PAGE. The gel was blotted onto PVDF membrane and
probedwith theanti-NICDantibody,withβ-actin as an internal control.
(B) Each band was quantified by grayscale scanning, and the relative
level of NICD was compared. Bars, means ± SD. **P < .01, n = 3.
Figure W7. hD1R bound to tumor vessels in vivo. Nude mice were
inoculated s.c. with U87 glioma cells (5 × 106) on the back. Mice
were injected i.p. with PBS or hD1R twice a week from the 7th day
of inoculation. At the ending day of the experiments, the tumors
were dissected 30 minutes after the last injection, sectioned, and
stained by using anti-CD31 (green) and anti–S-Tag (red).
Figure W6. hD1R repressed angiogenesis in vivo. P3 pups were
injected daily s.c. with PBS or hD1R. On P7, the retinas of the pups
were collected, flat-mounted, and stained with fluorescein-labeled
Griffonia simplicifolia Lectin I. The structures of the whole retinal
vasculature and the proximal, middle, and distal areas were shown.
Figure W8. hD1R enhanced the recruitment of perivascular cells. LLC cells were inoculated s.c. in nude mice, and the mice were treated
with PBS or hD1R. (A–C) Tumors were stained with anti-CD31 (green) and anti-NG2 (red). The NG2+ areas (B) and the ratio of NG2+ areas
versus CD31+ areas (C) were compared. (D, E) On the last day of the experiments, mice were injected with lectin (green) through the tail
vein. Tumors were dissected 30 minutes after the injection and were stained with anti-CD31 (red). The percentage of the perfused
vessels (lectin and CD31 double positive) was counted and compared (E). Bars, means ± SD. *P < .05, ***P < .001, n = 8.
Figure W9. mD1R did not affect lymphocyte differentiation and homeostasis. Mice were injected i.p. with PBS or mD1R twice a week
for 4 weeks. On day 28 after treatment, lymphoid organs were collected. Single-cell suspensions were prepared and analyzed by flow
cytometry with the indicated staining settings. (A) Bonemarrow (BM) B cell analysis shown by representative CD19+ B cell FACS plots along
with cell numbers on the side. (B) Spleen follicular (Fo) B and marginal zone (MZ) B cell distribution displayed by B220CD21CD23 profiles
of splenocytes. (C) Thymocyte subset analysis shown by CD4CD8 profiles of thymocytes. (D) Spleen T cell subset analysis presented by
CD4CD8 profiles of splenocytes. Bars, mean ± S.D. n = 5.
